Hemostemix Inc. Stock Price

TSXV:HEM Community·CA$10.9m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
2 Fair Values set on narratives written by author

Create Narrative

HEM Share Price Performance

CA$0.055

-0.07 (-56.00%)

CA$0.055

-0.07 (-56.00%)

CA$0.055

Wed, 17 Jun 26

Share Pricen/a

HEM Community Narratives

There are no narratives available yet.

Create Narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Moderate risk with imperfect balance sheet.

5 Risks

0 Rewards

View Full Analysis

Hemostemix Inc. Key Details

Last Reported Earnings

Mar 31, 2026

Next Reporting Earnings

n/a

: -0.021
: 0%
: 0%
: -66.1%

View Full Analysis

About HEM

Founded: n/a
Employees: n/a
CEO: Thomas Smeenk
WebsiteView website: hemostemix.com

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.